Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Current Assets (2017 - 2025)

Historic Current Assets for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $73.6 million.

  • Innate Pharma's Current Assets fell 3879.51% to $73.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $444.6 million, marking a year-over-year decrease of 2326.36%. This contributed to the annual value of $92.8 million for FY2024, which is 4203.81% down from last year.
  • Latest data reveals that Innate Pharma reported Current Assets of $73.6 million as of Q2 2025, which was down 3879.51% from $91.6 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Current Assets ranged from a high of $183.3 million in Q2 2022 and a low of $73.6 million during Q2 2025
  • Its 5-year average for Current Assets is $138.0 million, with a median of $156.2 million in 2021.
  • Per our database at Business Quant, Innate Pharma's Current Assets crashed by 9990.46% in 2021 and then surged by 1737.59% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Current Assets stood at $158.2 million in 2021, then fell by 9.8% to $142.7 million in 2022, then grew by 11.63% to $159.3 million in 2023, then crashed by 42.47% to $91.6 million in 2024, then fell by 19.72% to $73.6 million in 2025.
  • Its last three reported values are $73.6 million in Q2 2025, $91.6 million for Q4 2024, and $120.2 million during Q2 2024.